Alembic Pharmaceuticals Limited has informed the Exchange regarding Change in Auditors of the company.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals' board approved audited results for Q4 and FY ended March 31, 2025. Consolidated revenue from operations rose to Rs. 6,672.08 crores (vs Rs. 6,228.63 cr in FY24), while consolidated profit before tax grew to Rs. 707.18 crores from Rs. 631.83 crores. Consolidated profit after tax was Rs. 583.42 crores (vs Rs. 615.82 cr), with standalone PAT at Rs. 503.12 crores (vs Rs. 666.48 cr). The board recommended a dividend of Rs. 11 per share (550%), unchanged from last year. Statutory auditor M/s. K.C. Mehta & Co. LLP is being replaced by M/s. KKC & Associates LLP (formerly Khimji Kunverji & Co.) for a 5-year term after completion of the outgoing auditor's tenure. M/s. Samdani Shah & Kabra was also appointed as Secretarial Auditor for 5 years. The statutory auditors issued an unmodified opinion on the results.
Routine auditor rotation upon term completion is a standard governance event and not a red flag. FY25 PAT dipped on a standalone basis despite revenue growth, which may draw investor attention, but the unchanged dividend signals management confidence in cash generation.